Results 171 to 180 of about 249,566 (267)

Continuous Apomorphine Infusion in Multiple System Atrophy Real‐World Insights From a French Nationwide Retrospective Cohort

open access: yesMovement Disorders Clinical Practice, EarlyView.
Abstract Background Continuous subcutaneous apomorphine infusion (CSAI) is effective in Parkinson's disease but has not been evaluated in multiple system atrophy (MSA). Objective To assess the 6‐month efficacy and tolerability of CSAI in MSA patients. Methods French multicenter retrospective registry‐based analysis of CSAI use in MSA.
Simon Lamy   +16 more
wiley   +1 more source

Mind the Gap: Predictors of Osteoporosis Treatment Following Fragility Fracture in Parkinsonism

open access: yesMovement Disorders Clinical Practice, EarlyView.
Abstract Background Fracture risk is increased in Parkinson's yet this risk is often not addressed. Objectives Our objective was to study the extent to which osteoporosis was treated, and predictors of treatment in a large representative cohort with parkinsonism.
Katie C. Naylor   +2 more
wiley   +1 more source

Sex Differences in Fall Frequency, Risk Factors, and Outcomes in Parkinson's Disease: A Cross‐Sectional Analysis

open access: yesMovement Disorders Clinical Practice, EarlyView.
Abstract Background Female sex is an independent fall risk factor in Parkinson's disease (PD), yet sex‐specific fall patterns remain unclear. Objectives To compare sex‐specific fall risk and outcomes across PD, prodromal alpha‐synucleinopathy (PAS), and healthy controls (HC); estimate fall frequency across PD progression; and assess how sex modifies ...
Joaquin A. Vizcarra   +197 more
wiley   +1 more source

Analysis of adenylate cyclase activity in Japanese children with orthostatic dysregulation. [PDF]

open access: yesPLoS One
Sugiyama N   +9 more
europepmc   +1 more source

Disease‐Duration–Specific Percentiles for Prospective Subtyping of Parkinson's Disease: A PPMI‐Based Study

open access: yesMovement Disorders Clinical Practice, EarlyView.
Abstract Background Parkinson's disease (PD) is clinically heterogeneous, with variable progression rates that complicate clinical trial design. The data‐driven diffuse malignant (DM), intermediate (IM), and mild‐motor predominant (MMP) subtyping model has prognostic value but lacks disease duration–specific thresholds for prospective use in disease ...
Ahmed Negida   +4 more
wiley   +1 more source

Effect of COMT and UGT1A Variants on Clinical Response to Opicapone in Parkinson's Disease

open access: yesMovement Disorders Clinical Practice, EarlyView.
Abstract Background Parkinson's disease (PD) is the second most common neurodegenerative disease. Symptomatic treatment is based on dopaminergic replacement. With disease progression, the initial benefit of levodopa becomes inconsistent, and motor complications emerge.
Elena Ojeda‐Lepe   +15 more
wiley   +1 more source

Home - About - Disclaimer - Privacy